Antibody-dependent Cellular Cytotoxicity Against Primary HIV-infected CD4+ T Cells is Directly Associated with the Magnitude of Surface IgG Binding
Overview
Authors
Affiliations
Antibody (Ab)-dependent cellular cytotoxicity (ADCC) is thought to potentially play a role in vaccine-induced protection from HIV-1. The characteristics of such antibodies remain incompletely understood. Furthermore, correlates between ADCC and HIV-1 immune status are not clearly defined. We screened the sera of 20 HIV-1-positive (HIV-1(+)) patients for ADCC. Normal human peripheral blood mononuclear cells were used to derive HIV-infected CD4(+) T cell targets and autologous, freshly isolated, natural killer (NK) cells in a novel assay that measures granzyme B (GrB) and HIV-1-infected CD4(+) T cell elimination (ICE) by flow cytometry. We observed that complex sera mediated greater levels of ADCC than anti-HIV-1 envelope glycoprotein (Env)-specific monoclonal antibodies and serum-mediated ADCC correlated with the amount of IgG and IgG1 bound to HIV-1-infected CD4(+) T cells. No correlation between ADCC and viral load, CD4(+) T cell count, or neutralization of HIV-1(SF162) or other primary viral isolates was detected. Sera pooled from clade B HIV-1(+) individuals exhibited breadth in killing targets infected with HIV-1 from clades A/E, B, and C. Taken together, these data suggest that the total amount of IgG bound to an HIV-1-infected cell is an important determinant of ADCC and that polyvalent antigen-specific Abs are required for a robust ADCC response. In addition, Abs elicited by a vaccine formulated with immunogens from a single clade may generate a protective ADCC response in vivo against a variety of HIV-1 species. Increased understanding of the parameters that dictate ADCC against HIV-1-infected cells will inform efforts to stimulate ADCC activity and improve its potency in vaccinees.
Grunst M, Ladd R, Clark N, Gil H, Klenchin V, Mason R PLoS Pathog. 2023; 19(5):e1011407.
PMID: 37253062 PMC: 10256149. DOI: 10.1371/journal.ppat.1011407.
Kuriakose Gift S, Wieczorek L, Sanders-Buell E, Zemil M, Molnar S, Donofrio G J Virol. 2023; 97(2):e0163522.
PMID: 36749076 PMC: 9973046. DOI: 10.1128/jvi.01635-22.
Molinos-Albert L, Lorin V, Monceaux V, Orr S, Essat A, Dufloo J Nat Commun. 2022; 13(1):1944.
PMID: 35410989 PMC: 9001681. DOI: 10.1038/s41467-022-29511-1.
Thomas A, Coote C, Moreau Y, Isaac J, Ewing A, Kourtis A JCI Insight. 2022; 7(9).
PMID: 35324477 PMC: 9090239. DOI: 10.1172/jci.insight.159435.
Wang S, Yates N, Pollara J, Voronin Y, Stanfield-Oakley S, Han D NPJ Vaccines. 2022; 7(1):18.
PMID: 35140230 PMC: 8828892. DOI: 10.1038/s41541-022-00441-9.